RAW Nutrition Joins Forces with The Quality Group in Category-Defining Co-Ownership and Partnership
1.4.2025 15:00:00 CEST | Business Wire | Press Release
RAW Nutrition, the fast growing sport nutrition brand that combines unmatched quality with cutting-edge formulation, today announced its partnership with The Quality Group, the European leader in performance nutrition known for its state-of-the-art product development and uncompromising quality standards. RAW Nutrition, which was recognized in 2024 as the fastest-growing consumer packaged goods company by Inc. 5000, built its reputation by delivering high-performance nutrition trusted by athletes at the highest level, and this strategic partnership allows the company to take that commitment to growth and innovation to the next level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401643282/en/
RAW Nutrition Joins Forces with The Quality Group in Category-Defining Co-Ownership and Partnership
This alliance combines two like-minded companies that emphasize a shared priority of delivering the highest standards in quality and innovation in the nutrition sector. The Quality Group, with its two leading brands, ESN and More Nutrition, brings in its proven expertise in cutting-edge production and quality, supporting RAW Nutrition in sustainably scaling its brand.
Both companies share a strong focus on community and athletes. As part of this shared commitment, Chris Bumstead – Co-Owner of RAW Nutrition, six-time Mr. Olympia, and one of the most recognized names in the fitness world – will be working closely with The Quality Group to share his expertise in developing high-quality products that athletes and everyday consumers can benefit from. Chris’ second brand, BUM Energy – a dynamic energy drink label – will also become part of The Quality Group’s partnership portfolio.
“After many discussions with several global performance nutrition companies, we decided to enter a partnership with The Quality Group given that they understand all the opportunities and challenges that we’re about to face, and have navigated through them extremely successfully,” said Dom Iacovone, RAW Nutrition Co-Founder and CEO. “Going through our process, it was very important to me to find a strategic partner versus one that would just give us the most money. We have big goals at RAW Nutrition to build this brand as big as it can be and cooperating with The Quality Group is the first step to helping us navigate that.”
RAW Nutrition & The Quality Group: A New Chapter
Effective immediately, RAW Nutrition’s CEO and Co-Founder, Dom Iacovone, and co-owner Chris Bumstead will both become co-owners of The Quality Group.
In the coming months, RAW Nutrition will focus on growing their product offering and presence in the US market, reaching current and new consumers in new ways.
"Both RAW Nutrition and The Quality Group are rooted in strong communities,” said Heikki Takala, CEO of The Quality Group. “Just as RAW Nutrition engages and fuels athletes in the US, The Quality Group’s brands ESN and More Nutrition engage and enable a loyal, performance-driven customer base in Europe. This strategic partnership enables us to elevate our commitment to our communities, and we are excited to get to join forces with Dom and Chris Bumstead, who are successful entrepreneurs. Chris is a true global icon in our industry, and we believe this is great news for our community.”
RAW Nutrition and The Quality Group will remain independent partners as they seek to build long-term value for their consumers. Lazard acted as financial advisor and Fredrikson & Byron P.A. acted as legal advisor to RAW Nutrition.
What is RAW Nutrition
RAW Nutrition combines unmatched quality with cutting-edge formulation to provide athletes with the best fuel for peak performance, recovery, and overall well-being.
Product Snapshot:
- CBUM Itholate Protein (MSRP $54.99): Formulated by Chris Bumstead himself, this 25g pure whey isolate blend is engineered for lean muscle growth and rapid recovery.
- Creatine Monohydrate (MSRP $12.99): Spikes strength, generates muscular power, and improves muscle fullness.
- Essential Pre-Workout(MSRP $26.99): A powerhouse formula designed for all lifters from beginner to advanced, packing 4g L-Citrulline for serious pumps and 3.2g Beta Alanine to delay fatigue.
- RAW Grass Fed Whey Protein(MSRP: $49.49): Pure, grass-fed whey protein isolate, this high-quality, fast-digestive 25g protein powder supports muscle growth and recovery.
- Ready to Drink Protein Shake(MSRP $4.25): Raw Nutrition’s top-selling protein in a ready-to-drink format. 30g micro-filtered, grass-fed protein isolate, no fillers, no dyes—just pure fuel on the go.
To shop RAW Nutrition’s products or to learn more, visit getrawnutrition.com, or follow them on Instagram, LinkedIn, TikTok or YouTube.
About RAW Nutrition
RAW Nutrition is led by Dr. Domenic Iacovone, six-time Classic Physique Mr. Olympia Champion Chris Bumstead, and renowned bodybuilding coach Matt Jansen.Since its inception in 2019, RAW Nutrition has been recognized as the #1 fastest-growing sports nutrition company by Inc. 5000 and was named Brand of the Year by GNC and Vitamin Shoppe. All RAW Nutrition products are made with premium, clean ingredients, free from unnecessary fillers and additives. RAW Nutrition proudly carries the Informed-Sport certification, a mark of excellence that guarantees its products are rigorously tested for prohibited substances.
About The Quality Group
The Quality Group is the leading sports nutrition, supplements and health food company based in Germany. The company operates a unique digital direct-to-consumer & social commerce business model with its own production, logistics and technology. The two brands "ESN" and "More Nutrition" are strongly rooted in their respective communities and offer better-for-you and performance nutrition to help their customers to live a better life and achieve their personal goals. The Quality Group is headquartered in Elmshorn and employs more than 1.200 people. In 2023, the company generated revenues of more than EUR 680 million. The Quality Group is owned by its founders, an experienced management team and CVC Capital Partners, one of the leading Private Equity companies globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401643282/en/
Contacts
Press Contact
Taylor Georgeson
Jack Taylor PR
raw@jacktaylorpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Named a Visionary in the 2026 Gartner ® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press Release
Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of the report is available here. Boomi’s Agent Control Plane unifies agent connectivity, governance, context, and contro
Experian's New Documentary RECLAIM Shows How Financial Access and Innovation Are Creating Opportunity Around the World5.11.2026 16:00:00 CET | Press Release
For years, Almir dreamed of meeting his granddaughter in the United States. But unresolved debt stood in the way. Thousands of miles away in Arizona, Elizabeth faced mounting medical expenses after a health crisis. In London, Rochelle worked to regain control of her finances while caring for family members. Their stories, and others like them, are at the heart of RECLAIM: Stories of Passion and Perseverance, a new documentary from global technology and data company Experian that explores how access to financial tools, technology and support can help people overcome obstacles and pursue new opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105341861/en/ Behind-the-scenes photo from the filming of RECLAIM: Stories of Passion and Perseverance, an Experian documentary. Brody Frye, who received care from The MetroHealth System in Cleveland, Ohio, is featured in the film’s story about healthcare innovation and the p
Saudi Fund for Development Signs Six Development Loan Agreements Worth Over USD 403 Million with Syria5.11.2026 15:32:00 CET | Press Release
The Saudi Fund for Development (SFD) has signed six concessional development loan agreements worth more than USD 403 million with the Syrian Arab Republic, marking a significant step in supporting the country’s recovery through the rehabilitation of essential infrastructure, restoration of vital public services and improvement of living conditions for communities affected by years of conflict. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105350224/en/ HRH the Crown Prince and President of the Syrian Arab Republic Al-Sharaa witness signing of agreements (Photo: AETOSWire The agreements, signed under the directives of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, reflect the Kingdom’s continued commitment to supporting Syria’s development priorities. The signing ceremony was witnessed by Hi
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 15:00:00 CET | Press Release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
European Commission expands license for Alfasigma’s Jyseleca ® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 15:00:00 CET | Press Release
The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financial and investor media only. Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Commission (EC) has approved an additional indication to Jyseleca® (filgotinib) 200 mg and 100 mg film-coated tablets, an oral once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. A submission for UK approval has been made to the Medicines and Healthcare products Regulatory Agency (MHRA) and is under review. The European Commission’s approval is based on data that support a favourable benefit-risk profile for filgotinib, including efficacy and safety fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom